ArticleThe Journal of experimental medicine2023
Microbiome influencers of checkpoint blockade-associated toxicity.
Article in The Journal of experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- The skin microbiota drives cutaneous immune checkpoint inhibitor toxicity in genetically susceptible mice.Cell host & microbe · 2026Article
- Risk Factors and Biomarkers for Immune Checkpoint Inhibitor-mediated Hepatotoxicity: Emerging Insights and Future Perspectives.Journal of clinical and translational hepatology · 2026Review
- Review
- Biomaterials Based on Bacteria for Cancer Clinical Therapy.Biomaterials research · 2026Review
- Review
- Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy.Targeted oncology · 2026Article
- Microbiota-mediated mechanisms of mucosal immunity across the lifespan.Nature immunology · 2025Review
- Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.Immunotherapy · 2025Review
- A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.Cell chemical biology · 2025Article
- Review
- Review
- Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models.Applied and environmental microbiology · 2024Article
- Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.Japanese journal of clinical oncology · 2024Article
- Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity.European journal of medical research · 2024Article
- Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.Cancer immunology research · 2024Article
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events.Genome medicine · 2024Article
- [Advances in Predictive Research of Immune Checkpoint Inhibitors-related Adverse Events].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human.Immunological reviews · 2023Review
- The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy has greatly improved cancer outcomes, yet variability in response and off-target tissue damage can occur with these treatments, including immune checkpoint inhibitors (ICIs). Multiple lines of evidence indicate the host microbiome influences ICI response and risk of immune-related adverse events (irAEs). As the microbiome is modifiable, these advances indicate the potential to manipulate microbiome components to increase ICI success. We discuss microbiome features associated with ICI response, with focus on bacterial taxa and potential immune mechanisms involved in irAEs, and the overall goal of driving novel approaches to manipulate the microbiome to improve ICI efficacy while avoiding irAE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.